Click on the links below to preview selected pages from this course.
- Predictive Testing is the Basis of Personalized Treatment
- Predictive versus Prognostic
- Response Rates to Common Therapies
- Patient Benefit from Targeted Treatment Plans
- A prognostic factor is information concerning the patient that is used to help the clinician select the appropriate individuals for treatment with a s...
- Researchers have determined that only patients with tumors that demonstrate greater than 70% estrogen receptor (ER) positive cells will respond to hor...
- Types of Breast Cancer
- Incidence and Risk Factors
- Breast Cancer Classification
- Tumor Staging
- Use of Immunohistochemistry (IHC) for Breast Tumor Classification
- Adenocarcinoma is a very rare type of human breast cancer.
- Obesity, alcohol, and tobacco use are believed to have no impact on the risk for developing breast cancer.
- Theoretical Basis of Immunohistochemical Testing
- Basics of Immunohistochemistry (IHC)
- Variables Affecting Immunohistochemistry (IHC)
- Types of Antibodies
- Staining Patterns
- Which factors may impact staining by IHC techniques? (Select all that apply.)
- IHC alone is used to determine a primary diagnosis.
- Hormone Receptor Testing
- Introduction to Estrogen Receptors and Progesterone Receptors
- Hormonal Factors in Breast Cancer
- Clinical Application of Estrogen Receptor (ER) and Progesterone Receptor (PR) Testing
- Use of Immunohistochemistry (IHC) for Determining Estrogen Receptor (ER) and Progesterone Receptor (PR) Status
- Scoring and Reporting of Estrogen Receptor (ER) and Progesterone Receptor (PR) Testing
- Response Rates to Targeted Therapy
- The pattern for ER staining by IHC is localized within which part of the cell?
- There are no specific guidelines concerning how ER and PR results are scored or reported.
- Human Epidermal Growth Factor Receptor 2 (HER2)
- Introduction to Human Epidermal Growth Factor Receptor 2 (HER2)
- Immunohistochemistry (IHC) Testing Options For HER2
- Complimentary Testing Helps Assess HER2 Status
- Targeted Treatment Based on HER2 Status
- Impact of Variation in Test Results
- 2013 IHC Scoring Criteria from the American Society of Clinical Oncologists (ASCO) and the College of American Pathologists (CAP)
- HER2 over-expression in breast cancer is localized to chromosome 17.
- Only patients who over-express HER2 (eg, positive scores by IHC, CISH, or FISH) are candidates to receive Herceptin® (trastuzumab) treatment.
- HER2 Testing by In Situ Hybridization
- Regulation and Compliance with Predictive Markers
- Validation, Quality Control, Regulations -- Why?
- Validation Purpose
- Compliance Documentation
- Mandatory Proficiency Testing
- Comparison of 2007 to 2013 ASCO-CAP Guidelines for HER2 Testing
- Laboratories which are accredited by the College of American Pathologists (CAP) who perform HER2 testing are not required to participate in proficienc...
- Validation is required for all new test systems used in the laboratory prior to their use in patient testing.
Level of instruction: Intermediate
Intended audience: This course is intended for histology bench technicians and technologists, supervisors, and administrators.
Author information: Joelle Weaver MAOM, HTL(ASCP), QIHC is a certified histotechnologist with a broad range of practical histology experience within the clinical histopathology setting. She has received qualification in immunohistochemistry from the American Society for Clinical Pathology and Green Belt certification from Purdue University, West Lafayette, Indiana. Joelle's bachelor's degree was received from Bowling Green State University in Bowling Green, Ohio and her Master's Degree was awarded from Bluffton University in Bluffton, Ohio. She is a graduate of a NAACLS accredited histotechnology program, where she also served as a lead instructor, education coordinator, and program director. Joelle is currently an adjunct instructor in the Histotechnology Program with Harcum College in Bryn Mawr, PA.
Reviewer information: Donna M. Hedger, BS, HT(ASCP) is the Pathology Manager at Gwinnett Hospital System in Lawrenceville, Georgia. She graduated from Georgia Southern University with a Bachelor of Science in Biology. She is a certified histotechnician.
Course description: Toxicity, side effects, and unpredictable effectiveness have been the hallmark of anti-cancer therapies used in the past to treat breast and other primary cancers. Targeted therapies have been developed which reduce patient risk and provide remarkable improvement in patient outcomes. This course will discuss how predictive markers/testing are used to select patients who are most likely to respond positively to a specific breast cancer treatment, including current testing methodologies and compliance standards.